Azenta Inc (AZTA)vsResMed Inc (RMD)
AZTA
Azenta Inc
$34.20
+0.32%
HEALTHCARE · Cap: $1.48B
RMD
ResMed Inc
$221.89
-0.18%
HEALTHCARE · Cap: $32.46B
Smart Verdict
WallStSmart Research — data-driven comparison
ResMed Inc generates 821% more annual revenue ($5.65B vs $613.81M). RMD leads profitability with a 27.0% profit margin vs -20.0%. AZTA appears more attractively valued with a PEG of 0.53. RMD earns a higher WallStSmart Score of 67/100 (B-).
AZTA
Buy57
out of 100
Grade: C
RMD
Strong Buy67
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+35.0%
Fair Value
$46.86
Current Price
$34.20
$12.66 discount
Margin of Safety
-24.1%
Fair Value
$209.18
Current Price
$221.89
$12.71 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Earnings expanding 8778.0% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Growing faster than its price suggests
Strong operational efficiency at 30.9%
Safe zone — low bankruptcy risk
Every $100 of equity generates 23 in profit
Keeps 27 of every $100 in revenue as profit
Conservative balance sheet, low leverage
Generating 1.6B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
ROE of -11.5% — below average capital efficiency
Negative free cash flow — burning cash
Currently unprofitable
2.4% earnings growth
Comparative Analysis Report
WallStSmart ResearchBull Case : AZTA
The strongest argument for AZTA centers on Price/Book, EPS Growth, Debt/Equity. Revenue growth of 12.0% demonstrates continued momentum. PEG of 0.53 suggests the stock is reasonably priced for its growth.
Bull Case : RMD
The strongest argument for RMD centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 27.0% and operating margin at 30.9%. PEG of 1.31 suggests the stock is reasonably priced for its growth.
Bear Case : AZTA
The primary concerns for AZTA are Market Cap, Return on Equity, Free Cash Flow.
Bear Case : RMD
The primary concerns for RMD are EPS Growth.
Key Dynamics to Monitor
AZTA profiles as a turnaround stock while RMD is a mature play — different risk/reward profiles.
AZTA carries more volatility with a beta of 1.39 — expect wider price swings.
AZTA is growing revenue faster at 12.0% — sustainability is the question.
RMD generates stronger free cash flow (1.6B), providing more financial flexibility.
Bottom Line
RMD scores higher overall (67/100 vs 57/100), backed by strong 27.0% margins. AZTA offers better value entry with a 35.0% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Azenta Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Azenta Inc. is a premier provider of sample management solutions and life science tools, dedicated to enhancing laboratory efficiencies within the biotechnology and pharmaceutical industries. The company excels in innovative automation and comprehensive biorepository services, facilitating faster drug discovery while ensuring adherence to stringent regulatory standards. With a forward-looking strategy that leverages advanced storage technologies and strategic partnerships, Azenta is uniquely positioned to seize growth opportunities in the expanding global life sciences market. Its commitment to pioneering scientific research through sophisticated innovations underscores its potential appeal to institutional investors seeking exposure in the dynamic life sciences sector.
Visit Website →ResMed Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
ResMed is a San Diego, California-based medical equipment company. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea (such as CPAP devices and masks), chronic obstructive pulmonary disease (COPD), and other respiratory conditions.
Visit Website →Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?